To examine the consequences of AKT1 inhibition on Par-4 function in human colon cancer cells, AKT1 activity was suppressed by two complimentary approaches: an shRNA against AKT1 (pshAkt1) or phenylbutyl isoselenocyanate (ISC-4), a pharmacological inhibitor of AKT [34]. This evidence concerns the gene AKT1 and colonic neoplasm.